Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.42 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283330 | 0.89 | PDK1 (0.47) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL4689975 | 0.79 | KDM4E (0.50) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL911127 | 0.78 | MGLL (0.62) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL912073 | 0.77 | MGLL (0.53) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL595690 | 0.77 | MAPT (1.00) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL10364977 | 0.74 | MAPT (0.78) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL12902785 | 0.74 | MAPT (0.78) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL1226618 | 0.74 | MAPT (0.78) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL4692260 | 0.74 | PDK1 (0.45) | MAPTSMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL4689971 | 0.74 | ALDH1A1 (0.44) | MAPTSMN1; SMN2POLBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | MAPT 3850/4885SMN1; SMN2 4305/4885POLB 2086/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | MAPT 3850/4885SMN1; SMN2 4305/4885POLB 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.